POLYTROL BRACIN-D OXCIN-D MAXITROL DROPS TOBRADEX TOBRADEX MAXIDEX MAXITROL OINTMENT CECIDRON CIPOTIC-D D CORT DEXAMEX DEXAMEX DEXAMEX DEXAMEX BAYCUTEN-N BAYCUTEN-N EYEBRADEX BINADEX DEXIMOX DEXAMETHASONE DEXAMETHASONE DOSACHLOR ADRENAAL DEXAMETHASONE DEXADRON T DEXADRON EPODEX-N OCUDEX CINDEX DEXACHLOR DICON EYE DROPS DICON-N DEXAMETHASONE DEXAMIN-N DEXAMIN-N DEXAMEDRON DEXAMEDRON ALDRON ALDRON TOBRACIN-D FRADEX TRANCE DEXAMEK DEXAMEK IRZAMETHASONE IRZAMETHASONE FLUOROBIOPTAL BROMYCIN-D STERIDEX AMGYDEX AMGYDEX KANADEX KANADEX-N DEXAROID MEDIOFLOX-D MEDITROL MEDIDEX MEBRADEX MEDIDEX-C DECADRON DECADRON NEUDEX SPERSADEXOLINE SPERSADEX COMPOUND SPERSADEX DEXAMETHASONE DEXAMED FORTECORTIN DEXONE DEXONE PHESONE DEXACORT PLIDAXAN DEXATOB SANTODEX SANTODEX SANTIROL DEXOPTIC DEXOPTIC DEXOFLOX DEXOPTIC-C MYDEX METHAZONE DEXAMETHASONE DEXA N SHIRODEX SHIRODEX ORBATROL ORBATROL DEXAMETHASONE DEXAMETHASONE DEXAMETHASONE SULPHOFAX SULPHOFAX DEXAMETHASONE DEXAMETHASONE DEXAMETHASONE DEXAMETHASONE NEODEX ATNESON DEXAMETHASONE HAMAZONE ZOMADEX-N CHLORDEX DEXAFLOX DEXAMETHASONE RECADRON RECADRON FOCALIN TOBRAMET DEXCIP STERIBIOL POLYDEX OPTADEX OPTADEX-N METHASUL TOBRA-D Z-DEX TOBCYDEX DEXACOR DEXACOR DEXADRIN DEXADRIN DEXADRIN OCUTOB-DEX OCUTROL DEXAMETHASONE ERODEX-N FAIRSONE PRIMADEX N DEXAMETHASONE KENIDEX-N CARPILLA METHASONE DEXAMETHASONE METADEX METHOX UNISONE OPHTH-NEODEX OPHTH-TOBRA-D OPHTH-TOBRA-D OPHTH-DEX DECACHLOR DEXAMETHASONE DEXAMETHASONE DEXAMETHASONE DEXONIL TODEX POLDEC DEXAMETHASONE VEGATOB VEGADEX VEGADEX C OBRADEX DEXATEX MYRET METAAREX DANADEX DANADEX BRADEX FLADEXON DELTASALONE KLOZEN BECLOTRIM ORCYDEX METHADEX METHADEX N DEXSUL DEXER D SONE ORADEXON ORADEXON ORADEXON ORADEXON EPHADEX N D.DRON METHADO OCUTODEX QUINODEX MERRYSONE MERRYSONE

Dose: 0.5 to 24 mg
Single Dose: 12 (12.25)
Frequency: As recommended.
Route: IV,IM
Instructions: Once in Weeks

Dose: 0.2 mg/kg
Single Dose: 0.2 (0.2)
Frequency: 8 hourly
Route: Intramuscular
Instructions:

Dose: 20.8 mg
Single Dose: 21 (20.8)
Frequency: 6 hourly
Route: Intra Venous
Instructions: Initial dose followed by 3.3mg till 8th day then by daily reduction of 1.7mg.For 35 kg and over

Dexamethasone Sodium Phospate is the derivative of Dexamethasone. It is of Synthetic origin and belongs to Steroid. It belongs to Glucocorticoid agonist pharmacological group on the basis of mechanism of action and also classified in Corticosteroid Nasal pharmacological group.The Molecular Weight of Dexamethasone is 392.50. It is weakly alkaline drug, 6.75% solution of the drug is isotonic.

Dexamethasone is contraindicated in conditions like Diabetes mellitus,Hypertension,Psychosis,Osteoporosis,GI ulceration,Infections,Renal insufficiency.

The severe or irreversible adverse effects of Dexamethasone, which give rise to further complications include Glaucoma, Peptic ulceration, Myopathy, Osteoporosis, Posterior subcapsular cataract, Growth retardation, Aseptic bone necrosis, Ocular hypertension, Subcapsular cataract, Pancreatic disturbance, Cushing like features, Oedema, Retinal detachment, Moon face, Truncal obesity, Negative calcium balance.Dexamethasone produces potentially life-threatening effects which include Collapse, Suppression of hypothalamus-pituitary-adrenal axis. which are responsible for the discontinuation of Dexamethasone therapy.The symptomatic adverse reactions produced by Dexamethasone are more or less tolerable and if they become severe, they can be treated symptomatically, these include Nausea, Vomiting, Insomnia, Nervousness, Nocturia, Increased appetite, Obesity, Facial rounding, Fragility of skin, Euphoria, Glucose intolerance, nervousness, Nervousness, adrenal suppression, protein catabolism, lipid metabolism.

Dexamethasone is primarily indicated in conditions like Adrenocortical insufficiency, Anorexia in palliative care, Brain tumors, Cerebral oedema, Congenital adrenal hyperplasia, Dyspnoea, Dyspnoea in palliative care, Headache due to raised intracranial pressure in palliative care, Nausea and vomiting (chemotherapy induced), Pain due to nerve compression in palliative care, Palliative surgery., Raised intracranial pressure, Respiratory distress syndrome, Shock, Suppression of inflammatory and allergic disorders, and can also be given in adjunctive therapy as an alternative drug of choice in Asthma, Blood disorders, Connective tissue diseases, GI diseases, Liver diseases, Malignancy, Ocular diseases, osteoarthiritis of superficial joints, Osteoarthritis, Renal diseases.

Dexamethasone is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAlbendazoleAminoglutethimideAminoglutethimide accelerates the metabolism of Dexamethasone (reduced effects).AprepitantIncreased the AUC of dexamethasone, a CYP3A4 substrate, by 2.2-fold on Days 1 and 5 of chemotherpy when given in regimen. The oral dexamethasone doses should be reduced by approximately 50% when coadministered with aprepitant capsules)(125 mg/80 mg regimen), to achieve exposures of dexamethasone similar to those obtained when it is given without aprepitant capsules. A single dose of aprepitant capsules (40 mg) when coadministered with a single oral dose of dexamethasone 20 mg, increased the AUC of dexamethasone by 1.45-fold. Therefore, no dose adjustment is recommended.Carbamazepinecarbamazepine increase clearance of cortisteroids.DiazoxideHypotensive effect of Diazoxide antagonised by Dexamethasone.Dolasetron (Mesylate)EphedrineEphedrineEphedrine increase urinary excretion of DexamethasoneFosphenytoinGranisetron (HCl)IloprostIndinavir (Sulphate)NatamycinConcurrent use may increase the toxicity, therefore concomitant use is contraindicated. NateglinideConcurrent use may reduce the hypoglycemic action of Nateglinide.OxandroloneThe concomitant administration of oxandrolone and adrenal cortical steroids may increase the edema in patients with edema. The mechanism and clinical significance are unknown. Closer monitoring may be appropriate, especially in patients with conditions that may be aggravated by fluid retention.MinorPerindoprilTheoretical potential for DEXAMETHASONE [ORAL] reducing the HYPOTENSIVE effect of Perindopril Erbumine. ModeratePhenobarbitonephenobarbitone decrease plasma half life and bioavailibility of dexamethasone by 50%Phenytoin (Na)Phenytoin (Na)RhubarbPotassium deficiency can be increased by concurrent use.RifampicinRitonavirSaquinavirSorafenibmay also increase metabolism of sorafenib and thus decrease sorafenib concentrations.SunitinibMay decrease sunitinib concentrations.Technetium Tc-99m GluceptateUptake of technetium Tc 99m gluceptate in cerebral tumor or abscess may be decreased because of reduced peritumor edema caused by the Dexamethasone.Technetium Tc-99m OxidronateLong-term therapy with glucocorticoids may induce bone mineral depletion, thus causing decreased bone uptake of technetium Tc 99m oxidronate.VORICONAZOLEVoriconazole may increase the serum concentration of dexamethasone by decreasing its metabolismMonitor for changes in the therapeutic and adverse effects of dexamethasone if voriconazole is initiated, discontinued or dose changed. These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Measurement of Serum Digoxin by Immunoassay. Impairment of Glucose Tolerance Lowers basal TSH, FSH and LH Levels Reduced levels of Prolactin Reuces hGH response to various stimuli Lowering of Plasma cortisol,Potassium, and Oestrogens

Drug should not be given to Paediatrics, Pregnant Mothers, Cardiac / Hypertensive Patients, Geriatrics, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Inj, Cream, Gel, Ear Soln, Eye Oint, Soln or Susp Store Below 30°C. Do not Freeze. Protect from Sunlight. Oral Inhaler, Nasal Aerosol Store at room temperature, Below 40°C. Do not Freeze. Tab, Oral Elixir, Oral Soln Store in a well closed container, Below 40°C.

Dexamethasone should be used with caution in patients with active tuberculosis infection of respiratory tract or in untreated fungal, bacterial or systemic viral infections. Corticosteroids should only be used systemically with great caution in the presence of congestive heart failure (CHF), recent myocardial infraction (MI), hypertension, diabetes mellitus, epilepsy, glaucoma, hypothyroidism, liver failure, osteoprosis, peptic ulceration or renal impairment. Children may be at increase risk of some adverse effects, corticosteroid cause growth retardation and prolonged use is rarely justified. Passive immunization is recommended to non-immune patients who do come in contact with chickenpox or measles. Live vaccine should not be given to patients receiving high dose systemic corticosteroid therapy nor for atleast 3 months afterwards, killed vaccine or toxoids may be given, although the response may be attenuated. During prolong treatment with corticosteroids, patients should be examined regularly, sodium intake may need to be reduced and calcium and potassium supplement may be necessary. Patient should carry cards given full details of their corticosteroid therapy. Avoid use during pregnancy. Use nasal steroids with caution until healing has occurred. Dose adjustment required in patient with renal